Aims: To evaluate the clinical effectiveness of switching to insulin degludec (IDeg) in insulintreated patients with either type 1 diabetes (T1DM) or type 2 diabetes (T2DM) under conditions of routine clinical care.
| INTRODUCTION
Insulin degludec (IDeg) is a basal insulin with a unique mode of protraction that provides an ultra-long duration of action, exceeding 42 hours, and low day-to-day variability in blood glucose-lowering effect compared with insulin glargine U100 and U300. [1] [2] [3] Randomized controlled trials (RCTs) in adults, using a treat-to-target approach, have demonstrated that IDeg is associated with a reduced risk of hypoglycaemia, vs other insulin analogues, at equivalent levels of glycaemic control. [4] [5] [6] [7] [8] RCTs are the gold-standard for comparing the safety and efficacy of new therapies with existing treatment options; however, because of restrictive inclusion and exclusion criteria, the use of treat-totarget titration algorithms and the close management of patients during investigations, RCTs have a high degree of internal validity but lower generalizability. Therefore, it can be challenging to extrapolate the results to an unselected population. 9 Real-world studies are a valuable additional source of evidence that complement clinical trial data by assessing the external validity of new therapies, thus bridging the knowledge gap between RCTs and clinical practice.
Evaluating the clinical effectiveness of IDeg in a real-world population may help to inform the prescribing decisions of clinicians.
Single-centre non-interventional studies have reported reductions in glycated haemoglobin (HbA1c) and the risk of hypoglycaemia for patients switching to IDeg from other basal insulins, 10, 11 but there are currently no large multicentre studies evaluating the performance of IDeg in a real-world population.
The aim of the EUropean TREsiba AudiT (EU-TREAT) study was to evaluate the clinical effectiveness of switching to IDeg in a broad population of insulin-treated adult patients with either type 1 diabetes (T1DM) or type 2 diabetes (T2DM) in conditions that reflect routine clinical care in multiple centres across Europe.
| STUDY POPULATION AND METHODS
This was a European, multicentre, retrospective, non-interventional chart review study, using medical records of patients with T1DM or T2DM, who switched from any basal insulin to IDeg with a minimum of 6 months' follow-up after switching. All patients who received at least 1 prescription of IDeg were considered for study participation, including those who had discontinued IDeg at the time of inclusion in this study. Data were collected between December 5, 2015 and April 17, 2016 at outpatient clinics in Austria, Denmark, Germany, Greece, Italy and Switzerland.
A contract research organization (ICON plc, Dublin, Ireland) was responsible for investigational site selection and training, independent of the study sponsor. Potential investigators were randomly drawn in a sequential manner from databases of IDeg prescribers and contacted for participation. Confirmed investigators invited eligible patients in a consecutive manner to participate and sign the study informed consent form, starting with the patient who attended the clinic most recently and then working backwards. Competitive recruitment was used until the sample size was reached.
Two periods of medical history were reported: before (preswitch) and after (post-switch) the initiation date of IDeg. Baseline was defined as the closest date before switching to IDeg (up to 3 months before IDeg initiation). Outcome data, both pre-and postswitch, were collected in a AE 3-month window around the defined evaluation time points: 6 months pre-and post-switch, and at the time of switch, as well as 12 months pre-and post-switch, whenever Another secondary objective was to understand the use of IDeg in real life (ie, reasons for switching to and discontinuation of IDeg).
Hypoglycaemic events were those recorded by the physician/nurse in the patient charts. Nocturnal hypoglycaemia was defined as any event in which the words "nocturnal" or "night" (or their equivalent in the local language) were present in the patient records. Severe hypoglycaemia was defined as an episode requiring the assistance of another person to actively administer carbohydrate, glucagon or other corrective actions. For each patient, comparisons of hypoglycaemic episodes were based on similar time frames before and after switch (ie, −6 to 0 months vs 0 to +6 months and likewise for the 12-month period before/after comparisons, when appropriate).
Informed consent was obtained from patients, in accordance with the requirements of the Declaration of Helsinki, before any study-related activities were undertaken. A list of independent ethics committees for participating centres is provided online in Table S1 .
This trial is registered with ClinicalTrials.gov, number NCT02662114. 3 | RESULTS
| Statistical analyses

| Study population demographics and clinical characteristics
A total of 2550 patients were included in the study (T1DM = 1717, T2DM = 833). Baseline demographics and clinical characteristics are presented in Table 1 . There were 96 sites across 6 countries (Austria, 12; Denmark, 7; Germany, 45; Greece, 13; Italy, 13 and Switzerland, . Nearly all patients were on basal-bolus regimens. Before switching to IDeg, 51.7% and 42.3% of patients were receiving insulin glargine U100 and insulin detemir, respectively ( Table 1) . Half of the patients used once-daily basal insulin injection (Table 1) 74.5% on basal-bolus regimens. Before switching to IDeg, 49.8% and 31.1% of patients were receiving insulin detemir and insulin glargine U100, respectively. The proportion of patients injecting basal insulin once daily was 62.4% (Table 1) . There was no change in the number of OADs prescribed for each patient between the pre-and postswitch periods (data not shown). OAD use in patients with T2DM at baseline is presented in Table S2 . patients (data not shown).
| Glycaemic control
| Hypoglycaemia
In T1DM, switching to IDeg resulted in significantly lower rates of overall hypoglycaemia (21% reduction), overall non-severe hypoglycaemia (19% reduction), nocturnal non-severe hypoglycaemia (46% reduction) and severe hypoglycaemia (85% reduction) post-switch vs pre-switch, in the 6-month period comparison (Table S3 ; Figure 2A ).
The results from the 12-month post-switch vs pre-switch comparisons were similar (Table S4 ; Figure 2A ).
In T2DM, switching to IDeg resulted in significantly lower rates of overall hypoglycaemia (61% reduction), overall non-severe hypoglycaemia (60% reduction), nocturnal non-severe hypoglycaemia (90% reduction) and severe hypoglycaemia (92% reduction) postswitch vs pre-switch, in the 6-month period comparison (Table S5 ; Figure 2B ). Similar results were observed at 12 months, where comparisons were possible (Table S6 ; Figure 2B ). The proportion of patients experiencing ≥1 overall, nocturnal non-severe or severe hypoglycaemic event decreased significantly in the post-switch period in both T1DM and T2DM (Table S7 ; Figure 2 ). The pre-switch type of basal insulin did not have a significant effect on the rate of hypoglycaemia at follow-up in either T1DM or T2DM (data not shown).
| Insulin dose
In T1DM, at 6 months, daily basal insulin dose, daily prandial insulin dose and total daily insulin dose decreased by −3.15 U (−12%), −1.86 U (−7%) and −4.88 U (−11%), respectively, compared with baseline (P < .001 for all) ( Table 2) . At 12 months, daily basal insulin dose, daily prandial insulin dose and total daily insulin dose decreased by −3.32 U (−13%), −2.12 U (−8%) and −5.28 U (−11%), respectively, compared with baseline (P < .001 for all) ( Table 2 ).
In T2DM, at 6 months, daily basal insulin dose was unchanged;
however, daily prandial insulin dose and total daily insulin dose decreased by −2.00 U (−4%) (P = .015) and −2.48 U (−3%) (P = .006),
respectively, compared with baseline (Table 2) . At 12 months, daily basal insulin dose, daily prandial insulin dose and total daily insulin dose decreased by −1.54 U (−4%) (P = .036), −3.37 U (−6%) (P = .008) and −2.69 U (−4%) (P = .047), respectively, compared with baseline ( Table 2 ). In both T1DM and T2DM, when analysing changes in weight-adjusted dose (dose divided by body weight), the pattern of changes was the same as that seen for the primary analysis of dose (Table 2) . Hypoglycaemia rate ratios and odds ratios for A, T1DM and B, T2DM patients experiencing more than 1 hypoglycaemic event postvs pre-switch. Hypoglycaemia rate ratio was estimated using negative binomial regression model controlled for: age, BMI, gender, diabetes duration and duration of insulin therapy. Modelled results are based only on patients with complete data in both the pre-and post-switch period. Conditional logistic regression modelling was used to assess the likelihood of having ≥1 hypoglycaemic event. N/A, rate ratio could not be calculated because there were too few events in the post-switch period. Abbreviations: BMI, body mass index; CI, confidence interval; T1DM, type 1 diabetes; T2DM, type 2 diabetes 
| Body weight
In T1DM, body weight increased by 0.58 [0.41; 0.76] kg at 6 months, compared with baseline (P < .001), and was stable at 12 months (P = not significant vs 6 months) (Figure 3 ). In T2DM, body weight did not change significantly compared with baseline at either 6 or 12 months (Figure 3 ). Body weight was unchanged. 10 In another single-centre, real-world study by Landstedt-Hallin et al. in patients with T1DM (n = 357), HbA1c decreased by −3.3 mmol/mol (−0.3%) after switching to IDeg.
| Real-world use of IDeg
In the same study, the insulin dose was reduced by 12% post switch, and there was a 20% reduction in the rate of overall hypoglycaemia, along with a halving of the rate of nocturnal hypoglycaemia. 11 These findings are in line with those of our study in which HbA1c was significantly reduced in both T1DM and T2DM patients, bringing patients closer to target HbA1c levels. 12, 13 The absolute change in HbA1c in T2DM patients was clinically relevant and is comparable to the improvement observed in patients switching from neutral protamine Hagedorn to insulin glargine U100. 14 In T1DM, the decrease in Hypoglycaemia has acute medical consequences that include cognitive dysfunction, seizures, increased risk of cardiovascular events and death, but there is also a long-term impact on diabetes management resulting from the fear of hypoglycaemia, which can reduce patients' adherence to insulin regimens and lead to physicians setting less aggressive blood glucose targets. [15] [16] [17] In addition to the physiological and psychosocial burden, hypoglycaemia -and severe events in particular -is a major contributor to healthcare resource utilization and the cost of treating diabetes. 18 The large reduction in the risk of hypoglycaemia observed with IDeg in this study indicates that IDeg has the potential to improve glycaemic control and patients' quality of life, and could also play a role in reducing the cost burden of hypoglycaemia.
Another finding of this study that is worthy of note is the reason for discontinuing IDeg. In patients with T1DM, the most common reason for discontinuing treatment was "unspecified" ( Figure S2) . A large proportion of the patients who discontinued treatment with
IDeg were based in Germany where, following a change in reimbursement status, it is no longer marketed. Many of the patients who discontinued treatment for unspecified reasons did so because IDeg was no longer reimbursed.
This study is subject to limitations, including the observational, retrospective design of the study and the absence of a comparator arm, both of which present the possibility of confounding. For example, other factors could contribute to reductions in HbA1c and the risk of hypoglycaemia, including regression to the mean, selection bias in patients switched to IDeg, better management of patients by healthcare professionals after switching to a new basal insulin, including increased compliance with dietary recommendations, and a placebo effect. However, the fact that the effect of IDeg on HbA1C and hypoglycaemia was sustained after 12 months speaks strongly against a non-pharmacological "new treatment"
effect. In addition, the data from this study support those of RCTs that suggest that there is a real pharmacological benefit of switching to IDeg.
Another potential limitation to the study is that hypoglycaemic episodes were recorded by physicians/nurses, an approach that may not capture all events and could vary among sites; however, this
should not influence the rate ratio for the pre-and post-switch periods. Furthermore, closer monitoring of patients after switching should mean that more, not fewer, hypoglycaemic events are recorded in the post-switch period compared with the pre-switch period, which in turn means that the reduction in hypoglycaemia may be underestimated. Sodium glucose co-transporter-2 (SGLT2) inhibitors received marketing approval and became available for prescription during the study period. Co-use of SGLT2 inhibitors is associated with a lower insulin dose requirement in insulin-treated patients and there is no inherent risk of hypoglycaemia. 19, 20 This could bias the results for patients with T2DM if treatment with SGLT2 inhibitors commenced at the same time the patient switched to IDeg, but this is unlikely because physicians usually avoid initiating these 2 treatments at the same time. At the time of the study, insulin glargine U300 had just been approved (only 1 patient was receiving IGlar U300); therefore, we are unable to draw conclusions on the clinical outcomes for patients switching from insulin glargine U300 to IDeg. In summary, this study demonstrates that switching patients to
IDeg from other basal insulins improves glycaemic control and significantly reduces the risk of hypoglycaemia in routine clinical practice.
In patients with T1DM, insulin dose requirements were reduced after switching; in patients with T2DM, weight neutrality was observed.
These outcomes were consistent at 6 and 12 months after initiation of IDeg.
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